Time to first development of secondary autoimmunity | HR | 95% CI | P value |
Sex (male (57) vs female (113; ref.)) | 1.514 | 0.813 to 2.820 | 0.191 |
Age (<34 years (84; ref.) vs ≥34 years (86)) | 0.671 | 0.356 to 1.266 | 0.218 |
Annualised relapse rate at baseline | 0.926 | 0.665-.1290 | 0.650 |
Baseline-EDSS | 1.004 | 0.770 to 1.319 | 0.974 |
Disease duration since onset (yrs) | 0.997 | 0.931 to 1.066 | 0.921 |
Last previous DMT (naïve=ref. (35)) basic (52) | 2.043 | 0.770 to 5.418 | 0.151 |
NTZ (50) | 1.802 | 0.602 to 5.393 | 0.293 |
FTY (33) | 5.875 | 2.126 to 16.237 | <0.001 |
Results from our Cox proportional hazard model using an enter method to integrate all the covariates in the final analysis. For analysis of age as a covariate, we split our group according to the median. Reference categories are indicated for categorical covariates. Numbers in brackets in the first column indicate sample numbers for the respective covariate.
Bold values indicate p-values below 0.05
DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; FTY, fingolimod; NTZ, natalizumab.